NanoVibronix Announces Selection of Leading International Contract Manufacturer

- December 11th, 2018

NanoVibronix (NASDAQ:NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has appointed Quasar as its contract manufacturer for the PainShield, UroShield, WoundShield as well as other devices. As quoted in the press release: Quasar (http://www.quasar-med.com/) is a medical device manufacturer with over 30 years of … Continued

NanoVibronix (NASDAQ:NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has appointed Quasar as its contract manufacturer for the PainShield, UroShield, WoundShield as well as other devices.

As quoted in the press release:

Quasar (http://www.quasar-med.com/) is a medical device manufacturer with over 30 years of experience, serving major brands worldwide, with complex catheters, disposables, and FDA regulated assemblies. Quasar delivers a full lifecycle array of engineering services, including design-to-cost, jigs and tool design, as well as unique production process-design services that allow for the highest levels of efficiency and productivity. Quasar is ISO9001 and ISO13485 certified, as well as FDA registered.

Brian Murphy, Chief Executive Officer of NanoVibronix, commented, “We are delighted to announce the timely selection of Quasar as we begin our commercial ramp-up.  Quasar brings decades of medical device manufacturing experience in China with on-site western ownership and management.  Their turnkey solutions include supply chain management, production and quality engineering, manufacturing, testing and logistics. They have a demonstrated track record working with leading medical device companies and the ability to ensure high quality, high volume production to support our aggressive growth plans. By outsourcing manufacturing, we expect to generate meaningful cost savings, which should allow us to lower our selling price, increase production to meet revenue expectations, open additional markets, and improve profitability.”

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Leave a Reply